STOCK TITAN
  1. Home
  2. Sec-filings
  3. VERV
  4. [SC 14D9/A] Verve Therapeutics, Inc. Amended Tender Offer Recommendation

[SC 14D9/A] Verve Therapeutics, Inc. Amended Tender Offer Recommendation

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SC 14D9/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock VERV logo
Verve Therapeutics, Inc.

NASDAQ:VERV

VERV Rankings

#4349 Ranked by Market Cap
N/A Ranked by Dividends

VERV Latest News

Jun 17, 2025
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jun 2, 2025
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 28, 2025
Verve Therapeutics to Participate in Upcoming Investor Conferences
May 14, 2025
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
May 2, 2025
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VERV Latest SEC Filings

Jul 15, 2025
[8-K] Verve Therapeutics, Inc. Reports Material Event
Jul 15, 2025
[SC 14D9/A] Verve Therapeutics, Inc. Amended Tender Offer Recommendation
Jul 15, 2025
[SC TO-T/A] Verve Therapeutics, Inc. Amended Third-Party Tender Offer
Jun 25, 2025
[SC 14D9] Verve Therapeutics, Inc. Tender Offer Recommendation

VERV Stock Data

984.22M
84.54M
5.04%
90.12%
16.74%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON